The isothermal nucleic acid amplification technology market size is estimated to be USD 3,865.4 million in 2022 and is expected to witness a CAGR of 12.74% during the forecast period 2023-2033. Increasing frequency of infectious diseases, rising use of INAAT in place of PCR, expanding demand for affordable and reliable diagnostic techniques, technological developments is expected to propel the market growth. Furthermore, rapid developments in already-existing amplification technologies, and innovation of novel amplification techniques is expected drive the market growth. However, lack of knowledge about novel technologies is expected to hinder the growth.

Rapid developments in already-existing amplification technologies, and innovation of novel amplification techniques is projected to fuel the market. New applications for INAAT products are emerging as a result of the fast development of existing amplification technologies and the introduction of novel technologies. For instance, a study that used the LAMP technology that was published in the Analyst Journal in June 2022 illustrated that a smartphone-integrated equipment can instantly test for the Zika virus in a single blood drop. Such advances are probably continuing to grow the technique’s market penetration in the near future.

Increasing frequency of infectious diseases is predicted to fuel the market growth. The demand for improved diagnostic and treatment methods in healthcare institutions has grown due to the rise in infectious diseases including influenza, HIV, and tuberculosis. In 2020, tuberculosis resulted in the deaths of 1.5 million people worldwide, according to the WHO report 2021. After COVID-19 (above HIV/AIDS), tuberculosis is the second infectious disease that majorly cause of death worldwide and the 13th largest cause of death overall. In addition, about 10 million people acquired tuberculosis globally in 2020, 5.6 million of them were men, 3.3 million were women, and 1.1 million were children.

Segmentation

By Product

The market is categorized into reagents and instruments. In the global market, the reagents segment accounted for the largest revenue share in 2022 owing to its widespread use in hospitals and other primary healthcare facilities and growing accessibility of polymerases with high strand displacement capabilities. Additionally, it is predicted that INAAT diagnostics will increase in market penetration in the near future, and the use of the related reagents will grow substantially over the course of the forecast period. The demand for INAAT instruments is rising as a result of growing R&D interest in the creation of innovative diagnostics for emerging infectious diseases.

By Technology

The market is divided into HDA, NASBA, RPA, LAMP, TMA, SDA, RCA, SPIA, SMAP, NEAR, and others. In 2022, the LAMP (loop-mediated isothermal amplification) segment accounted for the highest revenue share due to the fact that technology supports a variety of detection methods, including lateral flow and agarose gel detection and real-time fluorescence employing intercalators. The method can therefore identify a variety of RNA and DNA targets in human samples, including the Zika virus and the SARS-CoV-2 virus. The technology’s resistance to inhibitors, that permits the use of unprocessed samples and slightly purified nucleic acids, also supports the demand for it.

By Application

The market is segregated into infectious disease diagnostics, blood screening, cancer, and others. In the global market, the infectious disease diagnostics segment accounted for the largest revenue share in 2022 owing to recent development of particular INAAT kits and the rising prevalence of HIV, hepatitis A and B, and sexually transmitted diseases. Furthermore, the market is anticipated to grow as a result of growing concerns about antibiotic resistance and increasing attention to the prevention of epidemic outbreaks in developing nations. Blood screening segment is the fastest growing in near future due to increasing number of blood transfusions around the world.

By End Use

The market is segmented into central & reference labs, hospitals, academic & research institutes and others. In 2022, the segment accounted for the largest revenue share owing to development of miniature point-of-care INAAT instruments, that allow for single-level access for hospital-based analysis. Similarly, the industry expansion is anticipated to be supported by growing throughput and automation provided by such technologies for the processing of numerous samples. The end-use segment for central and reference laboratories is expected to expand significantly over the course of the forecast period due to expanding usage of molecular diagnostic techniques in these laboratories and the rising number of reference laboratories.

Regional Markets

In 2022, North America region accounted for the highest revenue in the isothermal nucleic acid amplification technology market and is expected to maintain its dominance during the forecast period. This is attributed to its developed research infrastructure and rising demand for nucleic acid amplification-based diagnostics to prevent infectious disease.  Additionally, it is projected that a high per capita healthcare spending and rising interest in point-of-care diagnostic techniques will propel market expansion. Germany’s INAAT market held a sizeable proportion in 2022, owing to the country’s ageing population and strong attention on its healthcare systems. The World Bank predicted that 21.98% of the nation’s population would be over 65 in 2021. Based on this, it is anticipated that there will be a significant incidence of age-related diseases, which can enhance the market potential for efficient INAAT devices.

Competitor Insights

Some of the key players operating in the isothermal nucleic acid amplification technology market are Grifols, S.A. (Spain), Lucigen Corporation (US), Mast Group Ltd. (UK), Meridian Bioscience (US), Quidel Corporation (US), Genomtec SA (Poland), QIAGEN (Netherlands), bioMérieux SA (France), Tecan Trading AG (Switzerland), DiaSorin S.p.A.(Italy), Abbott Laboratories, Inc. (US), GE Healthcare (US), Illumina, Inc. (US), Becton, Dickinson & Company (US), New England Biolabs, Inc. (US), TwistDx Limited (US), EIKEN CHEMICAL CO., LTD. (Japan), Ustar Biotechnologies Ltd. (China), Jena Bioscience GmbH (Germany), OptiGene Limited (UK), Thermo Fisher Scientific, Inc. (US), Sysmex Corporation (Japan), Hologic, Inc. (US), PREMIER Biosoft (US), and mFluiDx (US).

To achieve a competitive edge, these businesses are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by businesses in this sector.

• For instance, the new Lyo-Ready Direct RNA/DNA LAMP and Lyo-Ready Direct DNA LAMP Saliva Mix master mixes for isothermal applications were introduced by Meridian Bioscience, Inc. in May 2022.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including product, technology, application, and end use from 2023 to 2033.

Report Scope:

Segmentation: Isothermal Nucleic Acid Amplification Technology Market Report 2022 – 2033

Product (Revenue, USD Million), 2022 – 2033

• Reagents
• Instruments

Technology (Revenue, USD Million), 2022 – 2033

• HAD
• NASBA
• RPA
• LAMP
• TMA
• SDA
• RCA
• SPIA
• SMAP
• NEAR
• Others

Application (Revenue, USD Million), 2022 – 2033

• Infectious Disease Diagnostics
• Blood Screening
• Cancer
• Others

End Use (Revenue, USD Million), 2022 – 2033

• Central & Reference labs
• Hospitals
• Academic & Research Institutes
• Others

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA